Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care
May 08, 2019 18:20 ET
|
Novartis Pharma AG
Xiidra (lifitegrast ophthalmic solution) 5% fits strategically within industry-leading USD 4.6 billion Novartis ophthalmic pharmaceutical portfolio, laying groundwork for front-of-the-eye pipeline...
Novartis startet 2019 mit starken Umsätzen und einer zweistelligen Steigerung des operativen Kernergebnisses[1], Einführung von Mayzent sowie Abspaltung von Alcon; Gewinnprognose angehoben
April 24, 2019 01:00 ET
|
Novartis Pharma AG
Die Transformation zu einem fokussierten Arzneimittelunternehmen schreitet mit der Abspaltung von Alcon voran; die folgenden Angaben beziehen sich auf die fortzuführenden Geschäftsbereiche[2] ...
Novartis entame 2019 avec une forte croissance des ventes et une hausse à deux chiffres du résultat opérationnel core[1], le lancement de Mayzent et le spin-off d'Alcon; profit annuel revu à la hausse
April 24, 2019 01:00 ET
|
Novartis Pharma AG
La transformation en une société axée sur les médicaments a continué avec le spin-off d'Alcon; les commentaires ci-après ne concernent que les activités poursuivies[2] Chiffre d'affaires net des...
Novartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded
April 24, 2019 01:00 ET
|
Novartis Pharma AG
Transformation to focused medicines company continued with the spin-off of Alcon; commentary below is on continuing operations[2] Continuing operations net sales up 7% (cc[1], +2% USD) driven by...
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
March 26, 2019 19:33 ET
|
Novartis Pharma AG
Mayzent® (siponimod) is the first and only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS) in over 15 years[1] Up to 80% of patients...
Novartis plans for Alcon spin-off on April 9, 2019
March 22, 2019 02:00 ET
|
Novartis Pharma AG
Alcon obtained approval for listing on SIX Swiss Exchange and New York Stock Exchange Alcon will seek effectiveness of Form 20-F registration statement from the US Securities and Exchange...
Novartis announces change in Sandoz leadership
March 14, 2019 02:15 ET
|
Novartis Pharma AG
Richard Francis, CEO Sandoz, to step down on March 31, 2019 Francesco Balestrieri, Head Region Europe, Sandoz, appointed ad-interim CEO Sandoz Basel, March 14, 2019 - Novartis announced...
Novartis issues summary financial information for the Alcon eye care business ahead of shareholder vote on proposed spin-off
February 25, 2019 17:55 ET
|
Novartis Pharma AG
Basel, February 25, 2019 - Novartis today published certain key financial information for the Alcon eye care business covering the full year 2018 ahead of a vote on the proposed 100% spin-off of...
Novartis erzielt 2018 ein kräftiges Umsatzwachstum bei gleichzeitiger Steigerung der Kerngewinnmarge, baut wegweisende Therapie¬plattformen auf und fokussiert das Unternehmen
January 30, 2019 01:00 ET
|
Novartis Pharma AG
Der Nettoumsatz steigt im Geschäftsjahr um 5% (kWk[1], +6% USD) dank starker Performance der Wachstumstreiber: Die Geschäftseinheit Pharmaceuticals wächst um 7% (kWk), getragen von Cosentyx mit...
Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018
January 30, 2019 01:00 ET
|
Novartis Pharma AG
Full year net sales up 5% (cc[1], +6% USD) driven by strong performance of growth drivers: Pharmaceuticals BU grew 7% (cc) driven by Cosentyx USD 2.8 billion (+36% cc) and Entresto USD 1.0 billion...